Why CSL (ASX:CSL) could be an ASX 50 share to buy

Is this biotech giant a buy?

| More on:
ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're looking to boost your portfolio with some quality shares, then you might want to look at the ASX 50 index. This index is home to some of the largest and highest quality shares on the Australian share market.

One ASX 50 share that could be worth considering is CSL Limited (ASX: CSL).

Why CSL?

CSL is one of the world's leading biotechnology companies. It comprises two businesses, CSL Behring and Seqirus. The former is a specialist in plasma-based products, whereas the latter business specialises in vaccines.

Combined, the two businesses have been underpinning solid sales and profit growth for CSL in recent years. And while plasma collection headwinds could subdue CSL's near term growth, its long term outlook appears very positive. This is thanks to increasing demand for its core therapies and vaccines, and its lucrative research and development (R&D) pipeline.

In respect to the latter, thanks to its consistent investment in R&D (~11% of sales each year), CSL has a pipeline filled to the brim with products that have the potential to generate millions and potentially even billions of dollars in sales each year.

One of these is CSL112, which is a novel apolipoprotein A-I infusion therapy that has been shown to have an immediate and significant impact on the ability to remove cholesterol from arteries. Its phase 3 trial is enrolling more than 17,000 patients from approximately 1,000 medical centres across the world, with the results due at the end of the year.

Another is is clazakizumab, which is being developed to treat kidney transplant rejection. This product alone could generate peak sales of US$5.4 billion.

Is the CSL share price in the buy zone?

While opinion is admittedly divided on whether the CSL share price is in the buy zone right now, one broker that is bullish is UBS.

It currently has a buy rating and $330.00 price target on the company's shares. Based on the latest CSL share price, this implies potential upside of almost 15% over the next 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »